Sanjeev Luther, President and CEO, Rafael Pharmaceuticals discusses how tumor cell metabolism has recently attracted substantial attention as an area for the development of drugs to treat cancer. Rafael is a company leading the field of cancer metabolism with their drug CPI-613 (devimistat) currently being tested in Phase 1, 2, and 3 clinical trials for patients with rare cancers, including pancreatic cancer, acute myeloid leukemia (AML) and Burkitt's lymphoma.
@RafaelPharma
#RafaelPharma #cancermetabolism #pancreaticcancer #CPI613
RafaelPharma.com
Download the transcript here
Empowered Patient Podcast